AMBIT BIOSCIENCES CORP 4
4 · AMBIT BIOSCIENCES CORP · Filed Nov 12, 2014
Insider Transaction Report
Form 4
FOLETTA MARK G
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2014-11-10$8.67/sh−8,000$69,360→ 0 totalExercise: $6.33Exp: 2024-05-14→ Common Stock (8,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-11-10$3.91/sh−14,000$54,740→ 0 totalExercise: $11.09Exp: 2024-01-22→ Common Stock (14,000 underlying)
Footnotes (1)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of September 28, 2014, (the "Merger Agreement"), among Ambit Biosciences Corporation ("Ambit"), Daiichi Sankyo Company, Limited ("Daiichi Sankyo"), and Charge Acquisition Corp., each option, whether vested or not vested, was cancelled and converted into the right to receive, (i) a cash payment equal to the excess, if any, of $15.00 (the "Closing Price") over such option's per share exercise price; and (ii) one non-transferable contingent value right ("CVR") issued by Daiichi Sankyo with the Contingent Value Rights Agreement, dated November 10, 2014, between Daiichi and Broadridge Corporate Issuer Solutions, Inc.